| FANCC — Fanconi Anemia Group C Protein | |
|---|---|
| Symbol | FANCC |
| Full Name | Fanconi Anemia Group C Protein |
| Chromosome | 9q22.33 |
| NCBI Gene | 2176 |
| Ensembl | ENSG00000144567 |
| OMIM | 603234 |
| UniProt | Q00597 |
| Protein Family | Fanconi anemia complementation group |
| Molecular Weight | ~64 kDa |
| Expression | Ubiquitous, high in bone marrow |
FANCC (Fanconi Anemia Group C Protein) is a core component of the Fanconi anemia (FA) DNA repair pathway, a crucial mechanism for maintaining genomic stability through the repair of DNA interstrand crosslinks (ICLs) [1][2]. Originally characterized in the context of Fanconi anemia—a rare inherited bone marrow failure syndrome—FANCC has emerged as an important player in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD) [3][4].
The Fanconi anemia pathway coordinates a network of proteins that detect DNA damage, stall DNA replication, and facilitate repair through homologous recombination and translesion synthesis [5]. FANCC functions as part of the FA core complex, which includes FANCA, FANCB, FANCC, FANCD2, FANCD1 (BRCA2), FANCE, FANCF, FANCG, and FANCL. This complex monoubiquitinates FANCD2, a key downstream effector that coordinates DNA repair activities.
Beyond its well-established role in hematopoiesis and cancer predisposition, recent research has revealed unexpected functions for FANCC in neuronal biology, mitochondrial function, and cellular stress responses that are highly relevant to neurodegenerative disease pathogenesis [6][7]. The convergence of DNA damage accumulation, mitochondrial dysfunction, and impaired stress responses in neurodegeneration provides a compelling framework for understanding FANCC's contribution to these processes.
The FANCC gene spans approximately 20 kb on chromosome 9q22.33 and consists of 14 coding exons [8]. The protein product comprises 558 amino acids with a molecular weight of approximately 64 kDa. Unlike many DNA repair proteins that contain recognizable functional domains, FANCC is relatively unstructured but contains several critical functional motifs:
N-terminal region (1-150 aa): Contains sequences important for protein-protein interactions within the FA core complex, particularly binding to FANCA and FANCG [9].
Central domain (150-400 aa): The most conserved region of FANCC, involved in protein stability and complex formation. This region contains binding sites for FANCD2 and other pathway components.
C-terminal region (400-558 aa): Contains regulatory sequences and nuclear localization signals that control FANCC trafficking between cellular compartments.
The expression pattern of FANCC is ubiquitous, with highest levels in bone marrow, thymus, and testis [10]. Within the brain, FANCC is expressed in neurons, astrocytes, microglia, and oligodendrocytes, with particularly high expression in regions vulnerable to neurodegeneration such as the hippocampus and substantia nigra.
The primary function of FANCC is in the Fanconi anemia pathway for ICL repair [11]. This pathway is essential for maintaining genomic stability, particularly in proliferating cells that undergo DNA replication. The process involves:
ICL detection: The FA pathway is activated when replication forks encounter ICLs, which block both leading and lagging strand synthesis.
Replication fork stalling: ATR/Chk1-mediated checkpoint activation stabilizes stalled forks and prevents collapse.
FA core complex assembly: The FA core complex (including FANCC) assembles at the site of damage and catalyzes monoubiquitination of FANCD2.
FANCD2 activation: Monoubiquitinated FANCD2 forms a complex with FAN1 nuclease and other repair proteins to cleave the ICL and facilitate repair.
Homologous recombination: RAD51-mediated strand invasion and DNA synthesis complete the repair process.
FANCC serves as a critical scaffold within the FA core complex, facilitating protein-protein interactions and ensuring proper pathway activation [12]. Loss of FANCC function disrupts the entire pathway, leading to profound DNA repair defects.
FANCC interacts with pro-apoptotic signaling pathways to regulate cell survival [13]. In response to genotoxic stress, FANCC can:
Inhibit caspase activation: FANCC directly binds to and inhibits caspase-8, preventing death receptor-mediated apoptosis.
Modulate p53 signaling: FANCC interacts with p53 to influence cellular outcomes following DNA damage.
Regulate Bcl-2 family proteins: FANCC affects the balance between pro-survival and pro-apoptotic Bcl-2 family members.
These anti-apoptotic functions are particularly important in cells with high proliferative potential, such as hematopoietic stem cells, where FANCC deficiency leads to progressive bone marrow failure.
Emerging evidence indicates that FANCC localizes to mitochondria and regulates mitochondrial homeostasis [14]. This function is distinct from its nuclear role in DNA repair and appears to be particularly important in post-mitotic cells like neurons:
Mitochondrial DNA repair: FANCC contributes to repair of mitochondrial DNA (mtDNA) lesions, including ICLs.
Mitochondrial dynamics: FANCC regulates mitochondrial fission and fusion through interactions with Drp1 and Mfn proteins.
Oxidative phosphorylation: FANCC-deficient cells show impaired complex I activity and reduced ATP production.
Mitochondrial membrane potential: Loss of FANCC leads to depolarization of the mitochondrial membrane and increased susceptibility to metabolic stress.
FANCC participates in broader cellular stress response networks beyond DNA repair [15]:
Oxidative stress: FANCC expression is upregulated in response to oxidative stress, and the protein contributes to detoxification of reactive oxygen species (ROS).
Proteostasis: FANCC interacts with components of the ubiquitin-proteasome system to regulate protein quality control.
Heat shock response: FANCC associates with heat shock proteins to facilitate protein folding and refolding under stress conditions.
Multiple lines of evidence connect FANCC to Alzheimer's disease pathogenesis [16][17]:
DNA damage accumulation: AD brains show extensive evidence of DNA damage, including increased γH2AX foci and PARP activation. The DNA damage burden correlates with disease severity and cognitive decline. FANCC deficiency would be expected to exacerbate this damage accumulation.
FANCC deficiency accelerates cognitive decline: A landmark study published in Nature Neuroscience demonstrated that FANCC deficiency in mouse models of AD leads to significantly faster cognitive decline [18]. The mechanism involves:
Mitochondrial dysfunction: FANCC deficiency exacerbates mitochondrial dysfunction in AD, including:
Neuroinflammation: FANCC deficiency in microglia leads to increased production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. This creates a feed-forward loop where neuroinflammation promotes further DNA damage and mitochondrial dysfunction.
FANCC plays a particularly important role in dopaminergic neuron survival [19][20]:
α-Synuclein aggregation: FANCC deficiency promotes α-synuclein aggregation through multiple mechanisms:
Mitochondrial complex I deficiency: Parkinson's disease is characterized by selective deficiency of complex I in the substantia nigra. FANCC deficiency synergizes with this deficit to:
FANCC polymorphisms: Genetic studies have identified FANCC polymorphisms associated with increased PD risk, particularly in early-onset cases [21]. These variants may reduce FANCC function and predispose to disease.
FANCC has been implicated in ALS through its role in DNA repair and stress response [22]:
Enhanced DNA damage: Motor neurons from FANCC-deficient mice show increased vulnerability to oxidative stress and excitotoxicity.
Impaired mitochondrial function: FANCC deficiency exacerbates mitochondrial dysfunction in ALS models.
Glial contribution: FANCC deficiency in astrocytes promotes neurotoxicity through increased inflammatory cytokine release.
While primarily an autoimmune demyelinating disease, MS involves DNA damage in neurons and oligodendrocytes. FANCC may play a protective role in:
Oligodendrocyte survival: Myelin-producing oligodendrocytes are highly vulnerable to DNA damage. FANCC deficiency increases oligodendrocyte death.
Remyelination: DNA repair capacity is crucial for efficient remyelination. FANCC deficiency impairs this process.
Axonal protection: FANCC helps protect axons from degeneration in the context of inflammatory demyelination.
FANCC is activated following DNA damage through the ATM/ATR checkpoint kinases [23]:
ATR activation: Replication stress and ICLs activate ATR, which phosphorylates Chk1 and promotes FANCD2 monoubiquitination.
ATM activation: Double-strand breaks activate ATM, which phosphorylates FANCD2 and facilitates its recruitment to damage sites.
Checkpoint restoration: FANCC contributes to checkpoint maintenance and repair completion.
FANCC interacts with p53 to influence cell fate decisions following DNA damage [24]:
p53 stabilization: FANCC can stabilize p53 protein levels.
Transcription regulation: FANCC modulates p53-dependent transcription of pro-apoptotic and cell cycle arrest genes.
Apoptosis vs. repair: The balance between FANCC and p53 influences whether cells undergo apoptosis or attempt DNA repair.
FANCC influences mitochondrial biology through multiple mechanisms [25]:
PGC-1α signaling: FANCC affects mitochondrial biogenesis through regulation of PGC-1α transcriptional activity.
SIRT1/AMPK: Energy sensing pathways interact with FANCC to coordinate metabolic adaptation to DNA damage.
mTOR signaling: FANCC can influence mTOR activity, affecting autophagy and mitochondrial quality control.
The identification of small molecules that activate FANCC function could provide therapeutic benefits in neurodegeneration [26]:
FANCC agonists: Compounds that enhance FANCC expression or function could improve DNA repair in neurons.
Combination approaches: FANCC activation combined with other interventions (e.g., antioxidants, mitochondrial protectors) may provide synergistic benefits.
Gene therapy approaches to restore FANCC function represent an alternative strategy:
Key questions remain about FANCC as a therapeutic target:
Optimal intervention point: Should therapy aim to enhance FANCC expression, stabilize FANCC protein, or enhance FANCC complex formation?
Cell type specificity: Which cell types (neurons, microglia, astrocytes) should be targeted?
Disease stage: Would FANCC-based therapy be effective in established disease or only in prevention?
Several mouse models exist for studying FANCC function:
FANCC knockout mice: These mice develop bone marrow failure and are highly susceptible to tumors.
Conditional knockouts: Tissue-specific deletion allows study of FANCC function in neurons, microglia, or other cell types.
Humanized models: Xenograft and humanized mouse models permit study of human FANCC function in vivo.
Commercially available reagents include:
| Condition | FANCC Expression Change | Tissue/Cell Type |
|---|---|---|
| Alzheimer's disease | Decreased in hippocampus | Brain |
| Parkinson's disease | Decreased in substantia nigra | Brain |
| ALS | Decreased in spinal cord | Spinal cord |
| Multiple sclerosis | Variable in lesions | Brain |
| Fanconi anemia | Biallelic mutations | Blood cells |